Role of the E3 Ubiquitin Ligase CBL Family in Cardiovascular Diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The ubiquitin-proteasome system is a fundamental cellular process increasingly considered for diagnostic and therapeutic strategies. Current research on Casitas B-lineage lymphoma (CBL) proteins primarily focuses on understanding its precise roles in the development of different diseases and exploring the feasibility of targeting CBL as a potential therapeutic target by inhibiting or enhancing its function.

On the one hand, blocking the interaction between Casitas B-lineage lymphoma and E2 by small molecules targeting the RING domain of CBL may enhance the activity of CBL-b and c-Cbl, potentially offering therapeutic value in cancer treatment. On the other hand, targeted deletion of the Casitas B-lineage lymphoma gene in specific cells can suppress CBL protein expression levels.

Thus, inhibiting the ubiquitination of Casitas B-lineage lymphoma or enhancing its negative regulation of specific signaling pathways may provide novel targets for drug development in cardiovascular disease.

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Mingze

Xingli Xu and Qinghua Cui. Role of the E3 Ubiquitin Ligase CBL Family in Cardiovascular Diseases. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0047

CVIA Journal